13 Results
Omalizumab Treats Multi-Food Allergy Better than Oral Immunotherapy
March 3, 2025
The high rate of allergic reactions and other intolerable side effects of oral immunotherapy in the NIH-funded trial explained the superiority of omalizumab.
Therapy Helps Peanut-Allergic Kids Tolerate Tablespoons of Peanut Butter
February 10, 2025
Eating slowly increasing amounts of peanut butter enabled 100% of kids with peanut allergy to consume 3 tablespoons of peanut butter without an allergic reaction.
Kidney Transplantation Between Donors and Recipients with HIV Is Safe
October 16, 2024
Kidney transplantation from deceased donors with HIV to recipients with HIV was safe and comparable to kidney transplantation from donors without HIV.
Introducing Peanut in Infancy Prevents Peanut Allergy into Adolescence
May 28, 2024
Feeding children peanut products regularly from infancy to age 5 years reduced the rate of peanut allergy in adolescence by 71%, even when the children ate or avoided peanut products as desired for many years. These new findings, from a study sponsored and co-funded by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), provide conclusive evidence that achieving long-term prevention of peanut allergy is possible through early allergen consumption. The results were published today in the journal NEJM Evidence.
Antibody Reduces Allergic Reactions to Multiple Foods in NIH Trial
February 25, 2024
A 16-week course of a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without an allergic reaction in a late-stage clinical trial.
Statement: NIH Trial Data Underpins FDA Approval of Omalizumab for Food Allergy
February 16, 2024
FDA has approved omalizumab for the reduction of allergic reactions, including anaphylaxis, that may occur with an accidental exposure to one or more foods in adults and children aged 1 year and older with food allergy. People taking omalizumab still need to avoid exposure to foods to which they are allergic.
Forgoing One Food Treats Eosinophilic Esophagitis as Well as Excluding Six
February 27, 2023
Eliminating animal milk alone from the diet of adults with eosinophilic esophagitis, or EoE, is as effective at treating the disease as eliminating animal milk plus five other common foods, a clinical trial funded by the National Institutes of Health has found.
NIH Study Links Specific Outdoor Air Pollutants to Asthma Attacks in Urban Children
January 4, 2023
Moderate levels of two outdoor air pollutants, ozone and fine particulate matter, are associated with non-viral asthma attacks in children and adolescents who live in low-income urban areas, a study funded by the National Institutes of Health has found.
Monoclonal Antibody Improves Cat Allergen Immunotherapy
October 11, 2022
An experimental approach to enhancing a standard cat allergen immunotherapy, often called allergy shots, made it more effective and faster acting, and the benefits persisted for a year after treatment ended.
Monoclonal Antibody Reduces Asthma Attacks in Urban Youth
August 10, 2022
A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income urban neighborhoods, a National Institutes of Health clinical trial has found.
NIH Launches Trial of Monoclonal Antibody to Treat Asthma in Urban Youth
June 2, 2022
The National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.
Trial Tests Strategy to Augment Response to COVID-19 Vaccines in Transplant Recipients
January 31, 2022
A study has begun to assess the antibody response to an additional dose of a COVID-19 mRNA vaccine in kidney and liver transplant recipients, either alone or with a concurrent reduction in immunosuppressive medication.
Oral Immunotherapy Induces Remission of Peanut Allergy in Some Young Children
January 20, 2022
A clinical trial funded by the National Institutes of Health has found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth.
